Bryce Point Capital LLC Invests $164,000 in Arrowhead Pharmaceuticals, Inc. $ARWR

Bryce Point Capital LLC purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,409 shares of the biotechnology company’s stock, valued at approximately $164,000.

Several other institutional investors and hedge funds have also bought and sold shares of ARWR. Bank of New York Mellon Corp grew its stake in Arrowhead Pharmaceuticals by 5.4% during the second quarter. Bank of New York Mellon Corp now owns 818,079 shares of the biotechnology company’s stock worth $12,926,000 after buying an additional 42,040 shares in the last quarter. Bank of Montreal Can lifted its holdings in shares of Arrowhead Pharmaceuticals by 24.0% during the 2nd quarter. Bank of Montreal Can now owns 24,918 shares of the biotechnology company’s stock worth $394,000 after acquiring an additional 4,818 shares during the period. Pinnacle Associates Ltd. boosted its position in shares of Arrowhead Pharmaceuticals by 49.9% during the 2nd quarter. Pinnacle Associates Ltd. now owns 211,561 shares of the biotechnology company’s stock worth $3,343,000 after acquiring an additional 70,399 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $491,000. Finally, Nisa Investment Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,308 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. TD Cowen raised Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 28th. Finally, B. Riley upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.14.

Insider Activity

In other news, insider James C. Hamilton sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. Following the transaction, the insider owned 212,122 shares in the company, valued at approximately $7,424,270. The trade was a 8.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 60,000 shares of company stock worth $1,725,000 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $37.85 on Wednesday. The stock has a 50-day moving average price of $33.34 and a two-hundred day moving average price of $22.26. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $43.69. The company has a market capitalization of $5.23 billion, a PE ratio of -29.57 and a beta of 1.13. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same period in the prior year, the company earned ($1.38) earnings per share. Analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.